A detailed history of Islet Management, LP transactions in Mirati Therapeutics, Inc. stock. As of the latest transaction made, Islet Management, LP holds 50,000 shares of MRTX stock, worth $0. This represents 0.98% of its overall portfolio holdings.

Number of Shares
50,000
Holding current value
$0
% of portfolio
0.98%

Shares

0 transactions
Quarter Operation Price Per share shares change shares Held SEC Form

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Islet Management, LP Portfolio

Follow Islet Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Islet Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Islet Management, LP with notifications on news.